News

Equithrive Products Now Available in Canada

Equithrive Equithrive Joint Metaborol Resverasyn Resveratrol

Equithrive Products Now Available in Canada

Lexington, Ky. - June 19, 2017 - Equithrive, maker of the only clinically proven joint supplement, is now available in Canada! Biological Prospects LLC, the developer of Equithrive® Joint and Metaboral®, has received regulatory approval to supply its products to customers in Canada. “We have had a lot of interest and requests from Canadian customers and veterinarians,” said Dr. Patrick Lawless, Founder, President and CEO of Biological Prospects. “Now for the first time we can sell direct to customers in Canada and provide horses there a product that has been proven in multiple university studies to reduce lameness and support...

Read more →


What Is Resverasyn and How Can It Help My Horse?

Equithrive Equithrive Joint Metaborol Resverasyn Resveratrol

What Is Resverasyn and How Can It Help My Horse?

The supposed health benefits of red wine have been touted for centuries, and more recently, scientists have taken a closer look at one specific compound contained in red grape skin: resveratrol. Numerous studies through the years have shown resveratrol to be a potentially effective treatment in humans for everything from slowing the cognitive decline in Alzheimers patients, to helping combat heart disease with its natural anti-inflammatory properties, and even fighting obesity. So it should come as no surprise that resveratrol based supplements are beginning to trickle into the equine health market. What's good for me should be good for my...

Read more →


Owner/rider Deanne Prusak shares her experience enrolling her horse in a clinical trial

Owner/rider Deanne Prusak shares her experience enrolling her horse in a clinical trial

The equine veterinary world is filled with research studies, new product developments and abundant opportunities to improve the life of horses in large and small ways. Have you ever considered participating in a clinical trial or wondered what it is like to participate in one? Deanne Prusak was faced with that opportunity and decided to participate in a clinical trial when her competitive trail horse, an 8-year-old Arabian, TA Kaiser+, came up lame at a NATRC ride in Louisiana in March 2015. After multiple treatments failed to resolve the situation, Prusak decided to participate in a clinical trial and she...

Read more →


EQUITHRIVE® LAUNCHES E-NEWSLETTERS: HORSE HEALTH, RESEARCH AND PROMOTIONS FEATURED

EQUITHRIVE® LAUNCHES E-NEWSLETTERS: HORSE HEALTH, RESEARCH AND PROMOTIONS FEATURED

Lexington, KY - February 9, 2017- Biological Prospects, the developer of  Equithrive® Joint and Metaboral™, is launching a new email newsletter series that will offer free informative horse healthcare news, research, and  promotions via two publications. The publications are designed for caregivers, owners, veterinarians and anyone with an interest in equine health. "Our company is research-based and we have a wealth of scientific and veterinary information available to share related to equine soundness, aging and metabolic topics. The digital newsletter format will provide health care in a brief, easy-to-read format, keeping readers informed on topics that impact their horses' daily lives....

Read more →


WATTS PRESENTS EQUITHRIVE® RESEARCH DURING AMERICAN ASSOCIATION OF EQUINE PRACTITIONERS CONFERENCE

Lexington, Ky.- December 7, 2016 - Dr. Ashlee E. Watts was a presenter at the annual American Association of Equine Practitioners (AAEP) conference in Orlando, Fla., detailing two years of clinical research results on the effects of Resveratrol on horses experiencing hock lameness. The study titled, "A randomized, controlled trial of the effects of Resveratrol administration in performance horses with lameness localized to the distal tarsal joints," provided proof that Equithrive® Joint is effective therapy for equine hock lameness.  Watts' research has created buzz in the horse world among veterinarians and caregivers as research in the equine supplement market is not commonly performed...

Read more →